Atorvastatin was the world's best selling drug in 2006 with global revenues of over $13B. Key patents protect 5-membered heterocycles at the core of the structure. Cresset reinvestigated the core of Atorvastatin using FieldStere, looking for novel, chemically tractable molecules to serve as potential alternative HMG-CoA reductase inhibitors.
Please click here.

To view the full case study please click here.